| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SARS2 |
| Uniprot No | Q9NP81 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 35-518aa |
| 氨基酸序列 | TTEKRN RNLLYEYARE GYSALPQLDI ERFCACPEEA AHALELRKGE LRSADLPAII STWQELRQLQ EQIRSLEEEK AAVTEAVRAL LANQDSGEVQ QDPKYQGLRA RGREIRKELV HLYPREAQLE EQFYLQALKL PNQTHPDVPV GDESQARVLH MVGDKPVFSF QPRGHLEIGE KLDIIRQKRL SHVSGHRSYY LRGAGALLQH GLVNFTFNKL LRRGFTPMTV PDLLRGAVFE GCGMTPNANP SQIYNIDPAR FKDLNLAGTA EVGLAGYFMD HTVAFRDLPV RMVCSSTCYR AETNTGQEPR GLYRVHHFTK VEMFGVTGPG LEQSSQLLEE FLSLQMEILT ELGLHFRVLD MPTQELGLPA YRKFDIEAWM PGRGRFGEVT SASNCTDFQS RRLHIMFQTE AGELQFAHTV NATACAVPRL LIALLESNQQ KDGSVLVPPA LQSYLGTDRI TAPTHVPLQY IGPNQPRKPG LPGQPAVS |
| 预测分子量 | 58,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于SARS-CoV-2重组蛋白的关键文献，简要总结如下：
---
1. **文献名称**: *SARS-CoV-2 Spike Glycoprotein Vaccine Design Enabled by Viral Structure*
**作者**: Wrapp, D. et al.
**摘要**: 通过重组技术表达并纯化SARS-CoV-2 Spike(S)蛋白的胞外域，利用冷冻电镜解析其三维结构。研究揭示了S蛋白的预融合构象，并证明其作为疫苗抗原的潜力，为后续mRNA疫苗设计提供了结构基础。
---
2. **文献名称**: *Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein*
**作者**: Walls, A.C. et al.
**摘要**: 重组表达SARS-CoV-2 S蛋白并分析其与宿主ACE2受体的结合特性。研究发现S蛋白的构象动态变化及关键表位，为抗体中和机制和疫苗开发提供依据。
---
3. **文献名称**: *SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor*
**作者**: Hoffmann, M. et al.
**摘要**: 利用重组S蛋白和假病毒系统，验证SARS-CoV-2入侵宿主细胞依赖于ACE2受体和TMPRSS2蛋白酶，并发现蛋白酶抑制剂可阻断感染，为抗病毒药物研发提供靶点。
---
4. **文献名称**: *Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates*
**作者**: Corbett, K.S. et al.
**摘要**: 基于重组S蛋白设计的mRNA疫苗在非人灵长类动物中诱导强效中和抗体和T细胞免疫，证实重组蛋白作为疫苗免疫原的有效性，支持其进入临床试验。
---
以上研究聚焦于重组S蛋白在结构解析、疫苗开发及病毒入侵机制中的应用，均为COVID-19研究领域的里程碑式成果。
SARS-CoV-2 recombinant proteins are engineered versions of viral structural components, primarily developed to study the virus’s biology, enable diagnostic testing, and support vaccine/therapeutic development. The spike (S) glycoprotein, responsible for viral entry via ACE2 receptor binding, is the most studied target. Its receptor-binding domain (RBD) and full-length S protein are commonly expressed in heterologous systems (e.g., mammalian, insect, or yeast cells) to ensure proper folding and post-translational modifications.
These recombinant proteins have been pivotal in COVID-19 research. They serve as antigens in serological assays to detect neutralizing antibodies, map epitopes for vaccine design, and screen therapeutics like monoclonal antibodies. Notably, subunit vaccines (e.g., Novavax’s NVX-CoV2373) use recombinant S proteins stabilized in prefusion conformation to elicit immune responses. Structural optimizations—such as proline substitutions, furin cleavage site deletions, or trimerization domains—enhance protein stability, expression yield, and immunogenicity.
The production process involves cloning synthetic genes encoding target proteins into expression vectors, followed by purification via affinity chromatography. Challenges include maintaining native-like conformation, scaling up manufacturing, and ensuring batch consistency. Recombinant proteins also face limitations compared to mRNA vaccines, such as requiring adjuvants to boost immunity and difficulties in adapting to emerging variants. Nonetheless, they remain critical tools for understanding SARS-CoV-2 pathogenesis, developing next-generation pan-coronavirus vaccines, and creating cost-effective biologics for global health equity. Their modular design and safety profile (non-infectious) make them versatile for both research and clinical applications.
×
